Overview
| Generic Names: | Fentanila [INN-Spanish]; Fentanyl citrate; Fentanylum [INN-Latin]; fentanyl |
|---|---|
| Trade Names: | Actiq; Duragesic; Duragesic-100; Durogesic; Fentanest; Fentanil; Nasalfent; Pentanyl; Phentanyl; Rapinyl; Sentonil; Sublimaze |
| Brand Mixtures: | Innovar Injection (droperidol + fentanyl citrate) |
| PharmGKB Accession Id: | PA449599 |
Description
A potent narcotic analgesic, abuse of which leads to habituation or addiction. It is primarily a mu-opioid agonist. Fentanyl is also used as an adjunct to general anesthetics, and as an anesthetic for induction and maintenance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1078) (source: Drug Bank)
Indication
For the treatment of cancer patients with severe pain that breaks through their regular narcotic therapy. (source: Drug Bank)
ATC Therapeutic Categories
- N01AH:Opioid anesthetics
- N02AB:Phenylpiperidine derivatives
Pharmacology, Interactions, and Contraindications
Mechanism Of Action
Opiate receptors are coupled with G-protein receptors and function as both positive and negative regulators of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine and noradrenaline is inhibited. Opioids also inhibit the release of vasopressin, somatostatin, insulin and glucagon. Fentanyl's analgesic activity is, most likely, due to its conversion to morphine. Opioids close N-type voltage-operated calcium channels (OP2-receptor agonist) and open calcium-dependent inwardly rectifying potassium channels (OP3 and OP1 receptor agonist). This results in hyperpolarization and reduced neuronal excitability. (source: Drug Bank)
Pharmacology
Fentanyl is an opioid analgesic. Fentanyl interacts predominately with the opioid mu-receptor. These mu-binding sites are discretely distributed in the human brain, spinal cord, and other tissues. In clinical settings, Fentanyl exerts its principal pharmacologic effects on the central nervous system. Its primary actions of therapeutic value are analgesia and sedation. Fentanyl may increase the patient's tolerance for pain and decrease the perception of suffering, although the presence of the pain itself may still be recognized. In addition to analgesia, alterations in mood, euphoria and dysphoria, and drowsiness commonly occur. Fentanyl depresses the respiratory centers, depresses the cough reflex, and constricts the pupils. (source: Drug Bank)
Food Interactions
Avoid alcohol. (source: Drug Bank)
Absorption, Distribution, Metabolism, Elimination & Toxicity
Biotransformation
Fentanyl is metabolized primarily via human cytochrome P450 3A4 isoenzyme system. (source: Drug Bank)
Protein Binding
80-85% (source: Drug Bank)
Absorption
Bioavailability is 92% following transdermal administration and 50% following buccal administration. (source: Drug Bank)
Toxicity
Fentanyl has an LD50 of 3.1 milligrams per kilogram in rats, and, 0.03 milligrams per kilogram in monkeys. The LD50 in humans is not known. (source: Drug Bank)
Isomeric SMILES Code:
CCC(=O)N(c1ccccc1)C2CCN(CC2)CCc3ccccc3 (source: Drug Bank)
The following genes are in curated knowledge about this drug.
| Gene | Relationship | Evidence | |
|---|---|---|---|
|
|
ABCB1 |
|
Publications |
|
|
CYP3A |
|
Publications |
|
|
CYP3A4 |
|
Publications |
|
|
CYP3A5 |
|
Publications |
A list of non-curated publications that mention this drug along with other genes is available.
Drug Targets
| Gene | Description | |
|---|---|---|
| OPRD1 |
|
(source: Drug Bank) |
| OPRM1 |
|
(source: Drug Bank) |
A list of non-curated publications that mention this drug along with other drugs is available.
Drug Interactions
| Drug | Description | |
|---|---|---|
| amiodarone |
|
Possible bradycardia, hypotension (source: Drug Bank) |
| amprenavir |
|
The protease inhibitor increases the effect and toxicity of fentanyl (source: Drug Bank) |
| cimetidine |
|
Cimetidine increases the effect of the narcotic (source: Drug Bank) |
| fluconazole |
|
The imidazole increases levels/toxicity of fentanyl (source: Drug Bank) |
| fosamprenavir |
|
The protease inhibitor increases the effect and toxicity of fentanyl (source: Drug Bank) |
| indinavir |
|
The protease inhibitor increases the effect and toxicity of fentanyl (source: Drug Bank) |
| itraconazole |
|
The imidazole increases levels/toxicity of fentanyl (source: Drug Bank) |
| ketoconazole |
|
The imidazole increases levels/toxicity of fentanyl (source: Drug Bank) |
| naltrexone |
|
Naltrexone may precipitate a withdrawal syndrome in opioid-dependent individuals (source: Drug Bank) |
| nelfinavir |
|
The protease inhibitor increases the effect and toxicity of fentanyl (source: Drug Bank) |
| rifampin |
|
Rifampin reduces levels and efficacy of fentanyl/alfentanyl (source: Drug Bank) |
| ritonavir |
|
Ritonavir increases the effect and toxicity of fentanyl/alfentanyl (source: Drug Bank) |
| saquinavir |
|
The protease inhibitor increases the effect and toxicity of fentanyl (source: Drug Bank) |
| voriconazole |
|
The imidazole increases levels/toxicity of fentanyl (source: Drug Bank) |
Non-Curated Information
A list of non-curated publications that mention this drug along with other diseases is available.
Additional Datasets
These datasets are minimally curated and are sorted alphabetically by title.
LinkOuts
Common Searches
Search PubMed
Search Medline Plus
Search PubChem
Search CTD
Non-Curated Publications
A list of non-curated publications that mention this drug is available.
